Trilogy International Partners Inc T.TRL.WT.A

Estrace generic

[alwaysmoving]

Of course our biggest problem right now is that Estrace has been approved as a generic. Now this doesn't mean it will for sure be manufactured, at the moment this is unclear. Although we know it won't impact sales or at least shouldn't for at least the next two quarters. Acerus needs to provide us with its thoughts on this matter and how they can position themselves to tackle the generic brand if it becomes available. The good thing going for us is our cash on hand... which is enough to say we're safe from overnight annihilation like many people are suggesting... it won't happen here. Right now we're trading right at our cash value which should be the "floor value" and thankfully we don't have much debt.. Just my two cents, although Acerus owes us all an explanation as to why they were unprepared for the Estrace generic approval and what their plan is going forward. I definitely don't think this company is dead but the road ahead has gotten a bit longer... if you're long the worst thing you can do is sell at these levels.